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The pattern recognition receptor Toll-like receptor 2 (TLR2) has been implicated in the response to several
human viruses, including herpes simplex viruses (types 1 and 2) and cytomegalovirus. We demonstrated that
varicella-zoster virus (VZV) activates inflammatory cytokine responses via TLR2. VZV specifically induced
interleukin-6 (IL-6) in human monocytes via TLR2-dependent activation of NF-B, and small interfering RNA
designed to suppress TLR2 mRNA reduced the IL-6 response to VZV in human monocyte-derived macro-
phages. Unlike other herpesviruses, the cytokine response to VZV was species specific. VZV did not induce
cytokines in murine embryonic fibroblasts or in a mouse cell line, although VZV did activate NF-B in a human
cell line expressing a murine TLR2 construct. Together, these results suggest that TLR2 may play a role in the
inflammatory response to VZV infection.
Varicella-zoster virus (VZV) is a pathogen that causes two
distinct clinical syndromes: varicella (chicken pox) as the pri-
mary infection and herpes zoster (shingles) upon reactivation
of VZV latent in sensory neurons. VZV infects human muco-
sal surfaces, followed by systemic viremia with spread to skin
and subsequent establishment of latency in neurons of cranial
and spinal dorsal root ganglia. Induction of the innate immune
response occurs during acute infection, which is characterized
by the release of alpha interferon (IFN-) and IFN- (1).
Within a few days, cell-mediated and humoral immune re-
sponses develop.
Toll-like receptors (TLRs) are a key component of the host
innate recognition system. At least 11 TLRs are expressed in
humans (23). Specifically, TLR2 interacts with viruses or their
components, including measles virus, hepatitis C virus, and
several herpesviruses, including cytomegalovirus and herpes
simplex virus (HSV) (2, 3, 4, 15). Activation of TLR2 by these
viruses, including some herpesviruses, is followed by the pro-
duction of inflammatory cytokines, including interleukin-6 (IL-
6), IL-8, and tumor necrosis factor alpha (TNF-). In addition,
the induction of IFN- by HSV involves TLR9 (11, 17).
VZV DNA can be detected in peripheral blood mononu-
clear cells (PBMC) during viremia (18), and monocytes have
been shown by reverse transcription-PCR to support produc-
tive infection of VZV (10). VZV infection is associated with
induction of inflammatory cytokines, including IL-1 produc-
tion by VZV-infected epidermal cells (12). Human mononu-
clear cells have been shown to produce TNF- in vitro in
response to VZV-infected fibroblasts (21). Evidence that VZV
infection activates monocytes to produce inflammatory cyto-
kines is the hallmark of a TLR-dependent innate immune
response.
Human monocytes and monocyte-derived macrophages nor-
mally express TLR2 and produce cytokines such as IL-1,
TNF-, and IL-6 in response to stimulation with TLR2 ligands,
including viruses. The present work demonstrates that TLR2
contributes to human inflammatory cytokine production dur-
ing VZV infection.
MATERIALS AND METHODS
Virus preparation. A clinical isolate of VZV was cultured in human embryonic
lung fibroblasts (HELF). HELF were grown in Dulbecco’s modified Eagle’s
medium (Gibco, Gaithersburg, MD) supplemented with 2% heat-inactivated
fetal calf serum (HyClone, Logan, UT). PFU (1  106) of stock VZV was added
to confluent HELF in a T-175 flask and removed after 2 h, and fresh culture
medium was added. When cytopathic effect reached 60 to 70% (72 to 96 h
postinfection), cells were harvested by trypsinization. VZV-infected HELF or
uninfected control HELF were stored at 1.5  107 HELF/ml at 80°C in tissue
culture medium with 10% dimethyl sulfoxide. Quantification was performed by
plaque assay. VZV stocks contained 2  106 to 4  106 PFU/ml. UV irradiation
of VZV-infected HELF for 60 min completely abrogated production of plaques.
A clinical respiratory syncytial virus (RSV) isolate was also cultivated in HELF
as a control for cellular proteins associated with a cytopathic virus. When cyto-
pathic effect reached 60 to 70%, cells were harvested and stored at 80°C at a
concentration of 1  106 PFU/ml.
Reagents and cells. Human embryonic kidney (HEK) 293 cells expressing
human TLR2 and CD14 were cloned as described previously (14). HEK cells
expressing human TLR9 and TLR4, murine RAW 264.7 cells expressing human
TLR2, and plasmid constructs containing human or mouse TLR2 were gifts from
E. Latz, E. Lien, and D. Golenbock (University of Massachusetts Medical
School). Cells were transfected with an NF-B firefly luciferase reporter plasmid
and a control Renilla reniformis luciferase plasmid by using a GeneJuice (Nova-
gen) transfection reagent. Human PBMC were isolated from heparinized blood
from healthy volunteers. The mononuclear cell fraction was collected from Iso-
prep gradients (Matrix, Hudson, NH), and monocytes were purified by differ-
ential adherence to fibronectin. Monocytes were seeded into 96-well plates at a
density of 5  104 cells/well or in 24-well plates at 5  105 cells/well in RPMI
(Gibco) with 18% autologous serum. For some experiments, cells were allowed
to differentiate into macrophages for 7 days. Mice deficient in TLR2 were
generously provided by Shizuo Akira. Murine embryonic fibroblasts (MEF) were
isolated as previously described (16). Acyclovir and polymyxin B were purchased
from Sigma-Aldrich (St. Louis, MO).
TLR and non-TLR ligands. Lipopolysaccharide (LPS) from Escherichia coli
serotype O11:B4 (Sigma, St. Louis, MO) was phenol reextracted to remove
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contaminating lipopeptides (8). Pam2CSK4 and Pam3CSK4 were purchased from
EMC Microcollections (Tu¨bingen, Germany). R-848 was a gift from 3M Phar-
maceuticals (St. Paul, MN). CpG 2006 DNA was purchased from Coley Phar-
maceutical (Kanata, Ontario, Canada). IL-1 was purchased from R&D Systems
(Minneapolis, MN) and TNF- from Peprotech (Rocky Hill, NJ).
siRNA preparation. Twenty-one-nucleotide double-stranded RNAs were
chemically synthesized as annealed oligonucleotides by Ambion (Austin, TX).
Small interfering RNAs (siRNAs) were stored in water at 20°C. Sequences
were predesigned by Ambion. The siRNA sequences used were as follows: for
TLR2, 5-GGC UUC UCU GUC UUG UGA C dTdT-3, and for TLR8,
5-GGG AGU UAC UGC UUG AAG A dTdT-3.
Transfection of siRNA. Adherent human monocyte-derived macrophages
were transfected with 60 pmol siRNA per 5  105 cells and 3 	l Lipofectamine
2000 (Invitrogen, Carlsbad, CA) in serum-free Dulbecco’s modified Eagle’s
medium for 4 h, rinsed, and then placed in fresh RPMI supplemented with 18%
autologous serum.
ELISA. Human IL-6 and human IL-8 were measured by Quantikine enzyme-
linked immunosorbent assay (ELISA) from R&D Systems (Minneapolis, MN).
Murine IL-6 and murine TNF- were assayed using OptEIA (BD Biosciences,
Franklin Lakes, NJ).
Flow cytometry. TLR2 expression on the surface of human monocyte-derived
macrophages was determined by flow cytometry. Cells were detached by using 5
mM EDTA in phosphate-buffered saline. To block nonspecific antibody binding,
cells were incubated with blocking buffer (phosphate-buffered saline with 20%
serum from human whole blood, male type AB [Sigma]) for 60 min on ice (20).
Cells were stained with anti-TLR2 monoclonal antibody (clone 2.1) labeled with
allophycocyanin (APC) (eBioscience, San Diego, CA) or with isotype control
antibody with APC (eBioscience, San Diego, CA) for 30 min on ice. Cells were
analyzed using a FACScan analyzer. For each assay condition, at least 10,000
cells were analyzed.
RESULTS
VZV activation of NF-B requires TLR2 and CD14. We
examined the ability of human cells with or without TLRs on
their surface to respond to cell-associated VZV. We used hu-
man HEK293 cells stably transfected with TLR2 and its core-
ceptor, the glycosylphosphatidylinositol (GPI)-anchored pro-
tein CD14 (HEK/TLR2/CD14). These cells were transiently
transfected with an NF-B luciferase reporter plasmid and a
Renilla luciferase plasmid for internal control. A 6-h challenge
revealed that cell-associated VZV activated NF-B through
TLR2 (Fig. 1A). UV irradiation of VZV-infected HELF did
not significantly reduce its ability to activate NF-B. Unin-
fected control HELF did not activate NF-B in HEK/TLR2/
CD14 cells. Positive controls included Pam3CSK4, a TLR2
ligand, and IL-1, a TLR-independent activator of NF-B. To
ensure that the induction of NF-B by VZV-infected HELF
was not related to viral-induced cytopathic effects in HELF,
RSV-infected HELF served as an additional control. VZV-
infected HELF induced NF-B to a 10-fold-greater degree
than did cytopathic effect-matched RSV-infected HELF in
HEK/TLR2/CD14 cells. Mycoplasma, a TLR2 ligand, was not
detected in VZV-infected HELF by PCR studies (mycoplasma
detection kit; American Type Culture Collection, Manassas,
VA), which excluded this potential contaminant as a cause of
the observed increase in NF-B activation. In additional ex-
periments, we used HEK expressing TLR2 without CD14
(HEK/TLR2). NF-B activation by VZV-infected HELF was
greatly enhanced after transfection and expression of the hu-
man CD14 plasmid but not with the control plasmid, suggest-
ing that CD14 augments the recognition of VZV as a TLR2
ligand (Fig. 1B). As expected, TLR-independent activation of
NF-B by IL-1 was not augmented by the presence of CD14.
HSV, another alpha-herpesvirus, interacts with TLR9 to in-
duce IFN- in dendritic cells (11, 17). To investigate a possible
interaction between TLR9 and VZV, we tested the capacity of
cell-associated VZV to induce NF-B in HEK293 cells stably
transfected with TLR9 (HEK/TLR9). Addition of VZV-in-
fected HELF did not activate NF-B in these cells (Fig. 1C).
CpG DNA served as a positive control activator of TLR9, and
TNF- served as a TLR-independent positive control. Since
TLR4 also interacts with viruses (13, 19), we tested the effects
of VZV on HEK293 cells transfected with TLR4 and MD2, an
endotoxin coreceptor. We found that NF-B was not specifi-
cally induced by VZV in HEK/TLR4/MD2 cells (Fig. 1D). LPS
and IL-1 were used for positive controls. Data from this assay
also indicate that the VZV and HELF stocks do not contain
LPS.
While UV irradiation of VZV did not appear to influence its
ability to induce NF-B in HEK/TLR2/CD14 cells, we wanted
to confirm that TLR2-mediated induction of NF-B by VZV-
infected HELF does not require synthesis of new viral DNA.
HEK/TLR2/CD14 cells were pretreated with acyclovir at 100
	g/ml for 30 min and then challenged with VZV-infected cells
in the presence of acyclovir, which inhibits the viral DNA
polymerase. The induction of NF-B was identical to that by
VZV-infected HELF without acyclovir in HEK/TLR2/CD14
cells (Fig. 1E). The activity of acyclovir was confirmed by
plaque inhibition assay (data not shown). In addition, NF-B
was induced with VZV-infected HELF that had been frozen
and thawed repeatedly. This diminishes the plaque titer of
VZV-infected cells more than 1,000-fold (M. Levin, unpub-
lished observation). Again, Pam3CSK4 and IL-1 served as
positive controls.
VZV induces inflammatory cytokines in human PBMC and
monocytes but not in murine cells. Acute VZV infection is
associated with an inflammatory response characterized by fe-
ver and cytokine production (1, 21). Human monocytes, which
are infected by VZV during acute infection, express TLR2 (3,
10). We challenged human monocytes with VZV-infected
cells. Challenge with VZV-infected HELF was associated with
the production of the cytokines IL-6 and IL-8 in a dose-de-
pendent manner, while addition of control uninfected HELF
was associated with minimal induction of IL-6 and IL-8 (Fig.
2A). Monocytes, which also express TLR4, secreted cytokines
in response to LPS as expected. We could not attribute cyto-
kine induction by VZV-infected HELF to LPS contamination,
since the VZV-infected HELF did not induce NF-B in HEK/
TLR4/MD2 cells (Fig. 1D). Furthermore, we treated some
monocytes with polymyxin B (10 	g/ml) for 30 min prior to the
addition of and in the presence of stimuli, which resulted in a
reduction of the cytokine response to LPS by greater than 90%
but did not affect the response to VZV-infected HELF (Fig.
2A).
In contrast to HSV, which can infect and replicate in many
types of cultured cells, VZV has a limited host range. To test
whether VZV induces inflammatory cytokines in mouse cells,
we stimulated MEF with VZV. MEF naturally express high
levels of many TLRs, including TLR2, and produce cytokines
such as IL-6 and MCP-1 in response to stimulation with TLR
ligands (including the TLR2 ligand Pam2CSK4) (16). VZV-
infected HELF did not induce cytokines in wild-type MEF,
whereas Pam2CSK4 induced IL-6 in cells from wild-type but
not TLR2 knockout mice in a dose-dependent manner, as
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FIG. 1. Cell-associated VZV is a specific ligand for TLR2. (A) HEK293 cells expressing human TLR2 plus CD14 were transfected with an
NF-B-driven firefly luciferase reporter plasmid and a Renilla luciferase reporter plasmid and were stimulated for 6 h with VZV-infected HELF,
UV-irradiated VZV-infected HELF, uninfected HELF, or RSV-infected HELF at 1:10 or 1:100 (ratio of HELF to HEK). Pam3CSK4 (100 ng/ml) and
TNF- (100 ng/ml) were used as positive controls. (B) HEK293 cells expressing human TLR2 were transfected with reporter plasmids and either a human
CD14 plasmid or a pcDNA3.1 control plasmid. Cells were stimulated with VZV-infected HELF or uninfected HELF. Pam3CSK4 (100 ng/ml) was used
as a CD14-enhanced, TLR2-dependent positive control. IL-1 (100 ng/ml) served as a CD14-independent, TLR2-independent activator of NF-B.
(C) HEK293 cells expressing human TLR9 were transfected with reporter plasmids and then challenged with VZV-infected or uninfected HELF. CpG
DNA (3 	M) acted as a TLR9-dependent activator of NF-B, and TNF- (100 ng/ml) was a TLR-independent activator of NF-B. Pam3CSK4 (100
ng/ml) or medium alone served as a negative control. (D) HEK293 cells expressing human TLR4 plus MD2 were transfected with reporter plasmids and
subsequently challenged with VZV-infected or uninfected HELF, LPS (10 ng/ml), or IL-1 (100 ng/ml). Pam3CSK4 (100 ng/ml) or medium alone served
as a negative control. (E) HEK293 cells expressing human TLR2 plus CD14 were transfected with reporter plasmids. Prior to stimulation, acyclovir was
added at 100 	g/ml for 60 min. Cells were then stimulated with VZV-infected or uninfected HELF or controls for 6 h in the presence of acyclovir. Bars
represent standard errors of the means for triplicate wells. RLU, relative light units.
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expected (Fig. 2B). LPS was used as a TLR4-dependent,
TLR2-independent positive control. Murine peritoneal exu-
date cells also failed to produce cytokines in response to VZV,
even though these cells produce IL-6 in response to the TLR2
ligands zymosan and Pam3CSK4 (data not shown).
In a further attempt to characterize the murine response to
VZV, we used RAW 264.7 cells, a mouse macrophage-like cell
line that constitutively expresses murine TLR2 and CD14. To
determine if the presence of human TLR2 could allow VZV to
induce cytokines in murine cells, we used RAW 264.7 cells that
were stably transfected with a human TLR2-yellow fluorescent
protein (YFP) construct (RAW/hTLR2). Expression of this
FIG. 2. Inflammatory responses to VZV-infected HELF are specific to cells of human origin. (A) Monocytes were seeded at a density of 50,000
cells per well in 96-well plates. VZV-infected or uninfected HELF were added to monocytes at a ratio of 1:1 or 1:10, or monocytes were challenged
with LPS (10 ng/ml) or Pam3CSK4 (50 ng/ml) for 8 h. IL-6 (upper panel) and IL-8 (lower panel) secretion into culture supernatants was measured
by ELISA. Additional monocytes were treated with polymyxin B (10 	g/ml). Basal levels of IL-6 and IL-8 in VZV-infected HELF contributed to
less than 20% of the cytokine measured. (B) MEF from wild-type (WT) and TLR2 knockout (TLR2-KO) mice were plated at 100,000 cells per
well in 96-well plates and stimulated with VZV-infected HELF (ratios of 1:1 and 1:10 compared to MEF), LPS (100 or 10 ng/ml), or Pam2CSK4
(100, 50, or 25 ng/ml) for 24 h. Secreted IL-6 levels were determined by ELISA. (C) Murine RAW 264.7 cells stably expressing a human TLR2-YFP
construct were plated at 50,000 cell per well in 96-well plates and stimulated with VZV-infected HELF, Pam3CSK4 (100 or 10 ng/ml), or LPS (100
or 10 ng/ml) for 24 h. Secreted murine TNF- levels were determined by ELISA. (D) HEK293 cells stably expressing CD14 were transiently
transfected with a murine TLR2 plasmid construct (mTLR2) or a human TLR2 plasmid construct (hTLR2) (or both) along with the NF-B
luciferase reporter plasmid. Cells were stimulated with VZV-infected HELF (1:10 ratio to HEK cells), Pam3CSK4 (100 ng/ml), or IL-1 (100
ng/ml) for 6 h. Bars represent standard errors of the means for triplicate wells.
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FIG. 2—Continued.
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construct was confirmed by examining YFP expression with
confocal microscopy (data not shown). RAW/hTLR2 cells
were not able to produce the NF-B-mediated cytokine TNF-
in the presence of VZV-infected HELF after 24 h (Fig. 2C),
although they were able to produce TNF- in response to the
positive controls Pam3CSK4 and LPS. We were thus unable to
use TLR2 knockout mice for additional VZV studies.
VZV is recognized by either human or murine TLR2. Al-
though human and mouse TLR2 share 70% amino acid iden-
tity by comparative amino acid sequence analysis, murine
TLR2 recognizes specific peptides in a species-specific manner
(5). To determine if VZV-infected HELF specifically activates
human but not mouse cells due to differences in the TLR2
molecules themselves or due to the contribution of a human
non-TLR cofactor, we transiently transfected HEK/CD14 cells
with either murine or human TLR2 along with the NF-B
luciferase reporter. The cells were then stimulated with VZV-
infected HELF or Pam3CSK4. Both VZV and Pam3CSK4 were
able to activate NF-B in the presence of either human or
murine TLR2 (Fig. 2D). Thus, human cells expressing murine
TLR2 are activated by VZV while murine cells expressing
human TLR2 are not, suggesting that a human-specific cofac-
tor or adapter molecule is required.
Inhibition of IL-6 secretion in macrophages by siRNA tar-
geting TLR2. In order to prove that TLR2 participates in the
activation of NF-B in response to cell-associated VZV in
vitro, we used siRNA that targeted human TLR2 in human
monocyte-derived macrophages. A 21-nucleotide sequence
targeting TLR2 from positions 75 to 90 in relation to the start
codon (TLR2 siRNA) was introduced into human macro-
phages by lipofection. siRNA targeting TLR8 from positions
416 to 434 (TLR8 siRNA) was used as a non-TLR2 siRNA
control in parallel tests for transfection-associated cell toxicity.
Transfection of TLR2 siRNA resulted in a maximal decrease
of surface TLR2 antibody staining 48 h after transfection as
measured by flow cytometry, shown in Fig. 3.
In these experiments, monocyte-derived macrophages were
transfected with TLR2 siRNA (or TLR8 siRNA as a control).
Forty-eight hours later, cells were stained with APC-conju-
gated antibody against TLR2. Cells transfected with TLR2
siRNA (Fig. 3, upper panel, shaded histogram) had a lesser
degree of TLR2 staining than cells transfected with control
TLR8 siRNA (Fig. 3, upper panel, thin-lined histogram).
TLR2 siRNA-transfected cells or control siRNA-transfected
cells were each stained with isotype control antibody (Fig. 3,
lower panel, bold-lined and thin-lined histograms, respec-
tively). Of note, cells transfected with control TLR8 siRNA
had full expression of TLR2 at the cell surface compared to
untransfected cells (data not shown).
We then measured IL-6 production by macrophages in re-
sponse to either VZV-infected HELF or the TLR2 ligand
Pam3CSK4 in human macrophages transfected with TLR2
siRNA or control siRNA. Based on flow cytometry data, we
predicted that the maximal knockdown of TLR2 by siRNA
occurs 48 h after transfection, so at this time point, macro-
phages were stimulated with either VZV or Pam3CSK4 (Fig.
4). As a control, some cells were transfected with siRNA tar-
geting TLR8 and stimulated with the TLR7/TLR8 ligand
R-848. Supernatants were collected after 8 h, and IL-6 was
measured by ELISA. Cells with TLR2 knockdown had a 30 to
40% decrease in IL-6 responses to the TLR2 agonists VZV-
infected HELF and Pam3CSK4 compared to that of control
cells with TLR8 knockdown. Accordingly, TLR8 siRNA trans-
fection caused a 50% reduction in IL-6 in response to R-848
(P 
 0.01) but not in response to VZV-infected HELF or
Pam3CSK4. As human TLR8 has been shown to interact only
with single-stranded RNA viruses (6) and not with double-
stranded DNA viruses, such as the herpesviruses, cytokine
induction by VZV is not expected to be dependent on activa-
tion of TLR8. Cells transfected with TLR2 siRNA (or control
siRNA) were stimulated with LPS to ensure that nonspecific
suppression from a particular siRNA did not account for dif-
ferences in cytokine production. All cells had a robust IL-6
response to LPS, which is mediated through TLR4. Conditions
were performed in triplicate, and the siRNA experiments were
FIG. 3. TLR2 knockdown with siRNA is detectable in human
monocyte-derived macrophages by using flow cytometry. Monocyte-
derived macrophages were transfected with siRNA against TLR2 (or
TLR8 as a control). After 48 h, cells were stained with APC-conju-
gated TLR2 antibody. Cells transfected with TLR2 siRNA (upper
panel, shaded histogram) had less TLR2 staining than cells transfected
with the control TLR8 siRNA (upper panel, thin-lined histogram).
Cells transfected with control siRNA and stained with isotype control
antibody served as a baseline reference (upper and lower panels,
bold-lined histograms). In addition, cells transfected with TLR2
siRNA were stained with isotype control antibody (lower panel, thin-
lined histogram). Geometric mean fluorescent intensity values for up-
per-panel histograms were 7.17, 8.06, and 12.2. Lower-panel histogram
values were 6.41 and 7.17. Max, maximum.
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performed using cells from three independent donors, with
similar statistical results.
DISCUSSION
Using HEK293 cells as a model, we demonstrated that VZV
induced NF-B activity when TLR2 and CD14 were expressed.
We then examined cytokine production in response to VZV in
human monocytes, a natural host cell for VZV, and found
significant induction of IL-6 and IL-8. We discovered that
murine cells expressing TLR2, of either human or murine
origin, did not produce cytokines in response to VZV, al-
though HEK293 cells expressing murine TLR2 were respon-
sive to VZV. Finally, partial silencing of TLR2 expression in
primary human macrophages by RNA interference decreased
the ability of these cells to secrete IL-6 after activation with
VZV.
Our finding that TLR2 activates inflammation in human
cells infected by VZV mirrors its role in infection by HSV, a
closely related virus, and by cytomegalovirus, a beta-herpesvi-
rus. TLR2 may participate in the host inflammatory response
to these viruses, which ranges from mild to severe. We also
found that various murine cells do not activate NF-B in re-
sponse to this virus, even when human TLR2 is expressed in
murine cells in vitro. VZV has a narrow host range restricted
to humans and selected cell types of primate and guinea pig
origin; mice and cells of murine origin are not susceptible to
VZV infection (22). In contrast, HSV has a broader host range
and activates both human and murine cells in a TLR2-depen-
dent manner. However, we demonstrated that activation of
NF-B by VZV can occur in human cells expressing murine
TLR2 sequences. Human coreceptors, including those in-
volved in viral entry, may play a role in TLR2 activation and
induction of inflammatory cytokines and thereby explain the
species specificity of IL-6 induction by VZV. Our data suggest
that human CD14 may participate in VZV signaling, as CD14
enhanced the activation of NF-B in HEK/TLR2 cells. At
present, we do not know which component of VZV activates
TLR2, except that TLR2-mediated induction of NF-B does
not appear to require live virus or viral replication. However,
immediate-early and early events following infection could
play a role. In ongoing studies, we are examining viral envelope
components to determine which can specifically act as a TLR2
ligand.
To demonstrate that TLR2 participates in the induction of
human inflammatory cytokines by VZV, we successfully estab-
lished a model that utilizes RNA interference in primary hu-
man cells. We achieved a functional knockdown of cellular
responses to the TLR2 ligand VZV and Pam3CSK4 of 30 to
40%. The similarity in degree to which IL-6 production was
reduced suggests that a large amount of the inflammatory
cytokine response by macrophages to cell-associated VZV is
due to its TLR2-activating properties. siRNAs have potentially
broad applications in the study of pathogens and TLRs. For
example, the role of TLRs may be established for microbial
pathogens that specifically trigger inflammation in human cells.
Furthermore, siRNAs against TLR8 can be used to character-
ize the role of TLR8 in cytokine induction by single-stranded
RNA viruses, which appear to be the natural ligand for TLR8
(6). This is advantageous since animal studies of TLR8 have
been lacking, as murine TLR8 appears to be nonfunctional (7,
9).
In summary, our results demonstrate that VZV induces cel-
lular activation of inflammatory pathways in a species-specific,
TLR2-dependent manner. These results suggest that, as with
HSV, TLR2 participates in the early immune response after
VZV infection and contributes to the clinical presentation of
symptomatic primary or reactivation disease with VZV, char-
FIG. 4. Cytokine induction by TLR2 ligands is diminished in cells with siRNA targeted against TLR2. Monocyte-derived macrophages were
transfected with either TLR2 siRNA or TLR8 siRNA. Forty-eight hours posttransfection, cells were stimulated for 8 h with VZV-infected HELF
(ratio 1:1), Pam3CSK4 (100 ng/ml), LPS (1000 ng/ml), or R-848 (10 	M). Bars represent standard errors of the means for triplicate wells. Asterisks
indicate a P value of 
0.01 by Student’s two-tailed t test comparing values of TLR2 siRNA- and TLR8 siRNA-treated wells for VZV-infected
HELF, Pam3CSK4, and R-848, respectively. Similar results were seen with donors in three independent experiments.
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acterized by fever and/or rash (15). This innate host immune
response may be linked with specific cell-mediated immune
responses that participate in severe complications of VZV
infection, including thrombocytopenia, encephalitis, hepatitis,
and pneumonitis. Such clinical findings are often associated
with the production of inflammatory cytokines that may be
linked with host TLR2 recognition of herpesviruses.
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